公开(公告)号：EP2010169A2

公开(公告)日：2009-01-07

申请号：EP07754872.5

申请日：2007-04-04

申请人： Nitromed, Inc. ,  University of Pittsburgh of the Commonwealth System of Higher Education

发明人： WORCEL, Manuel ,  SABOLINSKI, Michael ,  TAM, Sang, W. ,  MCNAMARA, Dennis, M.

IPC分类号： A61K31/21

CPC分类号： A61K31/21 ,  A61K31/34 ,  A61K31/502 ,  A61K45/06 ,  A61K2300/00

摘要： The invention provides methods for treating various indications and diseases in a patient in need thereof, wherein the patient has a C825T polymorphism in the G protein beta3 subunit (GNB3), comprising administering to the patient (i) at least one antioxidant compound or a pharmaceutically acceptable salt thereof; (ii) at least one nitric oxide enhancing compound; and (iii) optionally the best current therapy for the treatment of cardiovascular diseases. In one embodiment the antioxidant is a hydralazine compound or a pharmaceutically acceptable salt thereof and the nitric oxide enhancing compound is isosorbide dinitrate and/or isosorbide mononitrate.

公开(公告)号：EP1865770A2

公开(公告)日：2007-12-19

申请号：EP06749580.4

申请日：2006-04-07

申请人： Nitromed, Inc. ,  University of Pittsburgh of the Commonwealth System of Higher Education

发明人： WORCEL, Manuel. ,  SABOLINSKI, Michael ,  TAM, Sang, W. ,  MCNAMARA, Dennis, M.

IPC分类号： A01N33/24 ,  A61K31/13

CPC分类号： A61K31/34 ,  A61K31/502 ,  A61K45/06 ,  A61K2300/00

摘要： The invention provides methods for (a) reducing mortality associated with heart failure; (b) improving oxygen consumption; (c) treating heart failure; (d) treating hypertension; (e) improving the quality of life in a heart failure patient; (f) inhibiting left ventricular remodeling; (g) reducing hospitalizations related to heart failure; (h) improving exercise tolerance; (j) increasing left ventricular ejection fraction; (k) decreasing levels of B-type natriuretic protein; (1) treating renovascular diseases; (m) treating end-stage renal diseases; (n) reducing cardiomegaly; (o) treating diseases resulting from oxidative stress; (p) treating endothelial dysfunctions; (q) treating diseases caused by endothelial dysfunctions; (r) treating cardiovascular diseases; in a patient in need thereof, wherein the patient has at least one polymorphism in the endothelial nitric oxide synthase (NOS3) gene, comprising administering to the patient (i) at least one antioxidant compound or a pharmaceutically acceptable salt thereof; (ii) at least one nitric oxide enhancing compound; and (iii) optionally the best current therapy for the treatment of cardiovascular diseases. In one embodiment the antioxidant is a hydralazine compound or a pharmaceutically acceptable salt thereof and the nitric oxide enhancing compound is isosorbide dinitrate and/or isosorbide mononitrate.